NCT00103818

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
900

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Feb 2005

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2005

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

February 15, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 16, 2005

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2006

Completed
Last Updated

January 14, 2015

Status Verified

January 1, 2015

First QC Date

February 15, 2005

Last Update Submit

January 13, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patient-reported amount of sleep and time to fall asleep at night after 3 months

    After 3 months

Secondary Outcomes (3)

  • Patient-reported awakenings at night

    After 3 months

  • Sleep quality

    After 3 months

  • Functioning after 3 months

    After 3 months

Interventions

Duration of Treatment: 3 months

Also known as: MK0928

Duration of Treatment: 3 months

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adult outpatients who are between the ages of 18 and 64

You may not qualify if:

  • Adults who do not have a diagnosis of insomnia (a sleep disorder)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Roth T, Lines C, Vandormael K, Ceesay P, Anderson D, Snavely D. Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies. J Clin Sleep Med. 2010 Feb 15;6(1):30-9.

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

gaboxadol

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 15, 2005

First Posted

February 16, 2005

Study Start

February 1, 2005

Study Completion

October 1, 2006

Last Updated

January 14, 2015

Record last verified: 2015-01